CAR keys to unlock the intracellular immunopeptidome

Area of Science:

• Immunology
• Oncology
• Pediatric Medicine

Background:

• Pediatric neuroblastoma is a challenging childhood cancer with limited treatment options.
• Current immunotherapies often target cell surface antigens, but novel intracellular targets are needed.
• Oncoproteins expressed within cancer cells present potential targets for immune-mediated therapies.

Purpose of the Study:

• To identify and characterize novel targets for Chimeric Antigen Receptor T-cell (CAR-T) therapy in pediatric neuroblastoma.
• To investigate the potential of Major Histocompatibility Complex (MHC)-peptide complexes derived from intracellular oncoproteins as CAR-T targets.

Main Methods:

• Analysis of intracellular oncoprotein expression in neuroblastoma cells.
• Identification of MHC-peptide complexes presented on the cell surface.
• Design and validation of CAR-T constructs targeting these MHC-peptide complexes.

Main Results:

• MHC-peptide complexes derived from intracellular oncoproteins were identified in pediatric neuroblastoma cells.
• These complexes represent a novel class of targets distinct from traditional cell surface antigens.
• Preliminary data suggest these targets are suitable for CAR-T cell recognition and killing.

Conclusions:

• MHC-peptides from intracellular oncoproteins are promising novel targets for CAR-T therapy in pediatric neuroblastoma.
• This approach broadens the scope of targetable antigens for neuroblastoma immunotherapy.
• Further research is warranted to develop and clinically evaluate these novel CAR-T strategies.